Elevating R&D from Concept to Clarity
Strategic R&D Advisory · Cambridge, MA
Leva is an independent advisory practice for deep-tech ventures in medtech, diagnostics, and life sciences. I bring technical depth and operating experience to the decisions that shape strategic and technical direction.
From Roadmap to Reality
R&D strategy that survives capital constraints
Most strategic R&D plans break on the assumption that the next round closes on time. The plans that don't are sequenced backwards from the capital actually raised. I help R&D leaders make those calls early enough that they compound.
Technical diligence that catches what the deck doesn't
The hardest part of evaluating a deep-tech platform is what's been smoothed over — the assumption that won't hold at scale, the integration risk no one volunteered. I bring fifteen years of operating experience in medtech and life sciences to the questions that would change the answer.
Investor communication that matches the evidence
Investors who fund deep tech can tell the difference between conviction and optimism. I help technical leaders structure roadmap, risk, and runway so the story they tell aligns with what they actually believe.
Areas of Focus
- R&D Strategy & Sequencing: Mapping the technical work to the capital, partners, and timeline available. Most of the value is in deciding what not to do next.
- Technical Due Diligence: Independent assessment for venture capital, M&A, and strategic partnerships. Focus on what the deck doesn't volunteer.
- Platform De-risking: Designing the experiments that decide the next platform call — TRL and CRL together, not one a step ahead of the other.
- Investor & Board Communication: Helping technical leaders explain a complex platform to non-technical readers. Where the work is, what's been retired, what comes next.
Leva is a selective practice. The engagements I take on are the ones where the judgment compounds — depth over breadth, and clients who want a partner who's done the building, not just the advising.
About Me
Kyle C. Smith, PhD
My career has been spent building deep-tech ventures from founding concept to commercial launch. Twice I've taken novel microfluidic platforms from lab bench to manufactured product — building the R&D organization, raising the capital, structuring the partnerships, and navigating the pivots that turn working science into working companies. My advisory work draws directly from that operational experience.
The technical foundation is medtech and life sciences, anchored in research at MIT and MGH. Whether the engagement is technical due diligence, R&D strategy, or platform de-risking, the perspective is the same: someone who's done the building and brings that experience to the call.
Track Record
Major engagements that shape how I think and work.
Secured $38M in Funding & Launched First Commercial Product
As the first employee and founding team member at MicroMedicine, I built the R&D organization from scratch, led the development of the Sorterra cell processing platform, and directed the execution that secured $38M in milestone-based funding — from spin-out to commercial launch.
Engineered a Capital-Efficient Business Pivot
As Co-Founder and CTO of BendBio, I architected a strategic pivot from a capital-intensive instrument model to a high-margin consumables model, securing first revenues and preserving 100% founder equity in the process.
Created Foundational IP Anchoring a $35M Strategic Partnership
At Massachusetts General Hospital, I invented the foundational microfluidic technologies that launched multiple spinout companies and anchored a $35M strategic R&D partnership with Johnson & Johnson for next-generation diagnostic devices.
Approach
Every deep-tech venture reaches a moment where the technology is real, the team is capable, and the path forward is still unclear. The decision that follows — what to fund next, who to partner with, what to stop — usually shapes the next eighteen months more than the technology itself. The work I find most consequential is helping leadership think that decision through with technical depth and operating perspective in the same conversation.
Engagements run on the rhythm of those decisions, not on hours billed. The work happens in close partnership with leadership, usually a founder or CTO carrying both the technology and the business at once, and the value tends to compound when the questions are real and the time horizon is long enough for judgment to land. I keep the practice small for that reason: the engagements worth taking on are the ones that ask for attention that doesn't scale.